Marie‐Odile Petillon

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

Jean‐Luc Harousseau, Michel Attal, Hervé Avet‐Loiseau et al. · Journal of Clinical Oncology · 2010 · 529 citations · Full text

Medicine, Hematology, Oncology +15

High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma

Franck Morschhauser, Françoise Kraeber‐Bodéré, William A. Wegener et al. · Journal of Clinical Oncology · 2010 · 114 citations

Medicine, Hematology, Oncology +15

Lenalidomide is safe and active in <scp>W</scp>aldenström macroglobulinemia

Guillemette Fouquet, Stéphanie Guidez, Marie‐Odile Petillon et al. · American Journal of Hematology · 2015 · 26 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).

Jean‐Luc Harousseau, Hervé Avet‐Loiseau, Thierry Façon et al. · Blood · 2009 · 26 citations

Medicine, Hematology, Pharmacotherapy +16

Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.

Franck Morschhauser, John P. Leonard, Bertrand Coiffier et al. · Blood · 2005 · 26 citations

Medicine, Hematology, Oncology +14